Published in Value Health on October 26, 2009
Assessing the Costs and Cost-Effectiveness of Genomic Sequencing. J Pers Med (2015) 0.87
Vitamin K supplementation for the primary prevention of osteoporotic fractures: is it cost-effective and is future research warranted? Osteoporos Int (2012) 0.79
Beyond AWP . . . way beyond. Value Health (2009) 0.76
What's in a perspective? Value Health (2009) 0.75
Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med (2009) 11.51
A randomized controlled trial of telemonitoring in older adults with multiple health issues to prevent hospitalizations and emergency department visits. Arch Intern Med (2012) 5.00
Regulatory review of novel therapeutics--comparison of three regulatory agencies. N Engl J Med (2012) 4.50
The diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med (2009) 4.41
Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med (2005) 4.22
When choosing statin therapy: the case for generics. JAMA Intern Med (2013) 3.80
Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol (2009) 3.42
Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm (2003) 3.34
Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care (2012) 3.24
Second-line agents for glycemic control for type 2 diabetes: are newer agents better? Diabetes Care (2014) 2.99
Off-hour presentation and outcomes in patients with acute myocardial infarction: systematic review and meta-analysis. BMJ (2014) 2.87
Risk-stratification methods for identifying patients for care coordination. Am J Manag Care (2013) 2.40
Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care (2003) 2.33
Cumulative exposure to ionizing radiation from diagnostic and therapeutic cardiac imaging procedures: a population-based analysis. J Am Coll Cardiol (2010) 2.26
Lifetime costs of medical care after heart failure diagnosis. Circ Cardiovasc Qual Outcomes (2010) 2.19
Cumulative complexity: a functional, patient-centered model of patient complexity can improve research and practice. J Clin Epidemiol (2012) 2.16
Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty. Urology (2013) 2.16
The chest pain choice decision aid: a randomized trial. Circ Cardiovasc Qual Outcomes (2012) 2.15
Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Med Care (2014) 2.14
Costs of necrotizing enterocolitis and cost-effectiveness of exclusively human milk-based products in feeding extremely premature infants. Breastfeed Med (2011) 2.12
Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison. Appl Health Econ Health Policy (2012) 2.06
A prospective evaluation of computerized tomographic (CT) scanning as a screening modality for esophageal varices. Hepatology (2008) 2.02
The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort. Mayo Clin Proc (2012) 2.00
Generic atorvastatin and health care costs. N Engl J Med (2011) 1.95
Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial. Am J Med (2011) 1.84
Factors associated with 30-day readmission rates after percutaneous coronary intervention. Arch Intern Med (2011) 1.70
Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis (2004) 1.65
The implications of hospital acquired adverse events on mortality, length of stay and costs for patients undergoing radical cystectomy for bladder cancer. J Urol (2012) 1.58
Contemporary trends in nephrectomy for renal cell carcinoma in the United States: results from a population based cohort. J Urol (2011) 1.57
A systematic review and meta-analysis of randomized trials of carotid endarterectomy vs stenting. J Vasc Surg (2011) 1.56
Hospitalization costs for radical prostatectomy attributable to robotic surgery. Eur Urol (2012) 1.53
Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Transfusion (2009) 1.53
Disparities in access to hospitals with robotic surgery for patients with prostate cancer undergoing radical prostatectomy. J Urol (2012) 1.53
Effect of premium, copayments, and health status on the choice of health plans. Med Care (2008) 1.48
Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. Cardiovasc Drugs Ther (2004) 1.46
Projecting future drug expenditures--2004. Am J Health Syst Pharm (2004) 1.45
Where's the value in health care? Value Health (2006) 1.45
Chronic care model and shared care in diabetes: randomized trial of an electronic decision support system. Mayo Clin Proc (2008) 1.45
Increasing frequency of opioid prescriptions for chronic abdominal pain in US outpatient clinics. Clin Gastroenterol Hepatol (2011) 1.44
What have we learnt from the rosiglitazone saga? BMJ (2011) 1.44
Determinants of fluoroscopy time for invasive coronary angiography and percutaneous coronary intervention: insights from the NCDR(®). Catheter Cardiovasc Interv (2013) 1.43
Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. Value Health (2009) 1.43
Impact of a drug utilization review program on high-risk use of prescription controlled substances. Pharmacoepidemiol Drug Saf (2013) 1.42
An examination of the dynamic changes in prostate-specific antigen occurring in a population-based cohort of men over time. BJU Int (2012) 1.42
Effect of multiple chronic conditions among working-age adults. Am J Manag Care (2011) 1.41
Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000-2010. Med Care (2013) 1.40
Projecting future drug expenditures--2012. Am J Health Syst Pharm (2012) 1.37
Shared decision making for patients with type 2 diabetes: a randomized trial in primary care. BMC Health Serv Res (2013) 1.26
Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. J Manag Care Pharm (2006) 1.26
Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. J Manag Care Pharm (2009) 1.25
Effect of weekend hospital admission on gastrointestinal hemorrhage outcomes. Dig Dis Sci (2009) 1.22
Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value Health (2009) 1.22
Impact of the 2008-2009 economic recession on screening colonoscopy utilization among the insured. Clin Gastroenterol Hepatol (2011) 1.21
Out of context: clinical practice guidelines and patients with multiple chronic conditions: a systematic review. Med Care (2014) 1.20
Self-report of hypoglycemia and health-related quality of life in patients with type 1 and type 2 diabetes. Endocr Pract (2013) 1.20
Care management for Type 2 diabetes in the United States: a systematic review and meta-analysis. BMC Health Serv Res (2012) 1.19
Projecting future drug expenditures: 2011. Am J Health Syst Pharm (2011) 1.16
Risk models and patient-centered evidence: should physicians expect one right answer? JAMA (2012) 1.15
Medication adherence among community-dwelling patients with heart failure. Mayo Clin Proc (2011) 1.14
The economic burden of opioid-related poisoning in the United States. Pain Med (2013) 1.13
Protocol for the Osteoporosis Choice trial. A pilot randomized trial of a decision aid in primary care practice. Trials (2009) 1.12
Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI. Value Health (2009) 1.11
A randomized controlled trial of telemonitoring in older adults with multiple chronic conditions: the Tele-ERA study. BMC Health Serv Res (2010) 1.09
Cost-effectiveness analysis of pharmaceutical care in a medicare drug benefit program. Value Health (2003) 1.09
Evaluating the cost-effectiveness of statins. J Manag Care Pharm (2004) 1.08
Simulation optimization of PSA-threshold based prostate cancer screening policies. Health Care Manag Sci (2012) 1.06
Individuals with diabetes preferred that future trials use patient-important outcomes and provide pragmatic inferences. J Clin Epidemiol (2010) 1.06
Estimating the economic burden of food-induced allergic reactions and anaphylaxis in the United States. J Allergy Clin Immunol (2011) 1.05
Depression, healthcare utilization, and death in heart failure: a community study. Circ Heart Fail (2013) 1.04
Projecting future drug expenditures in U.S. nonfederal hospitals and clinics--2013. Am J Health Syst Pharm (2013) 1.02
The effects of incremental costs of smoking and obesity on health care costs among adults: a 7-year longitudinal study. J Occup Environ Med (2012) 1.02
Effectiveness of the head CT choice decision aid in parents of children with minor head trauma: study protocol for a multicenter randomized trial. Trials (2014) 1.01
Impact of new drugs and biologics on colorectal cancer treatment and costs. J Oncol Pract (2011) 1.00
Where do I send thee? Does physician-ownership affect referral patterns to ambulatory surgery centers? Health Aff (Millwood) (2008) 0.98
Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV. Value Health (2009) 0.98
Optimizing the start time of statin therapy for patients with diabetes. Med Decis Making (2009) 0.97
Understanding the underlying drivers of inpatient cost growth: a literature review. Am J Manag Care (2003) 0.96
Optimization of PSA screening policies: a comparison of the patient and societal perspectives. Med Decis Making (2011) 0.96
The impact of decision aids to enhance shared decision making for diabetes (the DAD study): protocol of a cluster randomized trial. BMC Health Serv Res (2012) 0.96
Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V. Value Health (2009) 0.96
Impact of physician assistant care on office visit resource use in the United States. Health Serv Res (2008) 0.94
Clinician's use of the Statin Choice decision aid in patients with diabetes: a videographic study nested in a randomized trial. J Eval Clin Pract (2009) 0.94
Recollection of childhood abdominal pain in adults with functional gastrointestinal disorders. Scand J Gastroenterol (2009) 0.94
Economic impact of Clostridium difficile infection in a multihospital cohort of academic health centers. Pharmacotherapy (2011) 0.94
Direct medical costs in patients with fibromyalgia: Cost of illness and impact of a brief multidisciplinary treatment program. Am J Phys Med Rehabil (2011) 0.94
30-day hospital readmission of older adults using care transitions after hospitalization: a pilot prospective cohort study. Clin Interv Aging (2013) 0.93
The Chest Pain Choice trial: a pilot randomized trial of a decision aid for patients with chest pain in the emergency department. Trials (2010) 0.93
Projecting future drug expenditures--2008. Am J Health Syst Pharm (2008) 0.93
Projecting future drug expenditures--2009. Am J Health Syst Pharm (2009) 0.92
'They leave at least believing they had a part in the discussion': understanding decision aid use and patient-clinician decision-making through qualitative research. Patient Educ Couns (2013) 0.92
Direct medical costs of constipation from childhood to early adulthood: a population-based birth cohort study. J Pediatr Gastroenterol Nutr (2011) 0.91
Effects of ambulatory-care pharmacist consultation on mortality and hospitalization. Am J Manag Care (2003) 0.91
Which design for which question? An exploration toward a translation table for comparative effectiveness research. J Comp Eff Res (2012) 0.91
Anaemia and the risk of injurious falls in a community-dwelling elderly population. Drugs Aging (2008) 0.90
The relationship of postoperative complications with in-hospital outcomes and costs after renal surgery for kidney cancer. BJU Int (2012) 0.89
Projecting future drug expenditures--2006. Am J Health Syst Pharm (2006) 0.89
Impact of a palliative care consult service. Am J Hosp Palliat Care (2013) 0.89
Contemporary trends of in-hospital complications and mortality for radical cystectomy. BJU Int (2012) 0.89
The impact of asthma medication guidelines on asthma controller use and on asthma exacerbation rates comparing 1997-1998 and 2004-2005. Ann Allergy Asthma Immunol (2011) 0.89